Faculty from Roswell Park Comprehensive Cancer Center are among the international experts invited to share their research findings at the American Society of Clinical Oncology (ASCO) annual meeting ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, ...

ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focuson advanced or metastatic ...

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of ...

Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced endomet ...

The challenge, open from May 7 to June 7, invites school and university students to design a poster that answers the question ...

Researchers are arguing over whether ‘disruptive’ or ‘novel’ science is waning – and how to remedy the problem.